Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 11 | 2018 | 384 | 1.620 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 301 | 0.940 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 142 | 0.890 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 93 | 0.780 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 4 | 0.670 |
Why?
|
| Genotype | 1 | 2014 | 735 | 0.430 |
Why?
|
| Mutation | 3 | 2018 | 466 | 0.290 |
Why?
|
| Carcinoma, Small Cell | 3 | 2015 | 21 | 0.270 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 77 | 0.190 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 199 | 0.190 |
Why?
|
| Pyrazines | 1 | 2018 | 11 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 4 | 0.160 |
Why?
|
| Pyrazoles | 1 | 2018 | 65 | 0.160 |
Why?
|
| Prognosis | 2 | 2018 | 1362 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.150 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 58 | 0.150 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2016 | 2 | 0.150 |
Why?
|
| Female | 9 | 2018 | 18173 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 189 | 0.140 |
Why?
|
| Male | 8 | 2018 | 17815 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 546 | 0.140 |
Why?
|
| Survival Rate | 1 | 2018 | 795 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2016 | 139 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 401 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 208 | 0.130 |
Why?
|
| Humans | 11 | 2018 | 29123 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 179 | 0.130 |
Why?
|
| Aged | 6 | 2018 | 9492 | 0.120 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2013 | 4 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 9 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2018 | 3112 | 0.120 |
Why?
|
| Thymoma | 1 | 2013 | 5 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 2013 | 4 | 0.120 |
Why?
|
| Myeloid Cells | 1 | 2013 | 35 | 0.120 |
Why?
|
| Immune Tolerance | 1 | 2013 | 67 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2109 | 0.110 |
Why?
|
| Neoplasms | 1 | 2017 | 611 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 139 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 320 | 0.070 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2005 | 13 | 0.070 |
Why?
|
| BCG Vaccine | 1 | 2005 | 7 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 51 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 118 | 0.060 |
Why?
|
| Tea | 1 | 2004 | 3 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 525 | 0.060 |
Why?
|
| Middle Aged | 5 | 2018 | 10834 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 56 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 281 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 246 | 0.050 |
Why?
|
| Adult | 4 | 2018 | 8426 | 0.050 |
Why?
|
| Mice | 2 | 2016 | 2370 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2018 | 3101 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 40 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 16 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2018 | 143 | 0.040 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 15 | 0.040 |
Why?
|
| Clone Cells | 1 | 2017 | 36 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 18 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2017 | 23 | 0.040 |
Why?
|
| Genes, ras | 1 | 2017 | 26 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 69 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 440 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 22 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2016 | 60 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2016 | 30 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 249 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 436 | 0.040 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2016 | 44 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 90 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 141 | 0.040 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2015 | 1 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2015 | 8 | 0.030 |
Why?
|
| Endonucleases | 1 | 2015 | 4 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 30 | 0.030 |
Why?
|
| Mitosis | 1 | 2015 | 22 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 40 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 23 | 0.030 |
Why?
|
| Camptothecin | 1 | 2015 | 48 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 38 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 425 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 68 | 0.030 |
Why?
|
| Pneumonia | 1 | 2015 | 61 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 142 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 572 | 0.030 |
Why?
|
| Apoptosis | 1 | 2016 | 337 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 3719 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 681 | 0.030 |
Why?
|
| Models, Biological | 1 | 2016 | 373 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2013 | 10 | 0.030 |
Why?
|
| Smoking | 1 | 2017 | 427 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 641 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 47 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 158 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2013 | 63 | 0.030 |
Why?
|
| Animals | 2 | 2016 | 7299 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2016 | 666 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 980 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 1131 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 91 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 413 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 167 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 711 | 0.020 |
Why?
|
| African Americans | 1 | 2017 | 1373 | 0.020 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2005 | 2 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2005 | 39 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2005 | 69 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2004 | 169 | 0.020 |
Why?
|
| Quality of Life | 1 | 2005 | 816 | 0.010 |
Why?
|